ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00400556|
Recruitment Status : Completed
First Posted : November 17, 2006
Last Update Posted : November 17, 2006
Hematopoietic stem and progenitor cells (HSPC) are used for transplantation in patients undergoing high dose therapy for the treatment of a range of cancers.
- HSPC are collected from the bloodstream after treatment with medications that cause the HSPC to move from the bone marrow into the bloodstream, a process called mobilization
- between 5 and 60% of patients can fail to collect enough HSPC for a transplant, using current mobilization techniques
- this study aims to assess the safety of combining a derivative of vitamin A, ATRA with G-CSF (the drug most commonly used to mobilize HSPC)
- ATRA has never been combined with G-CSF for mobilization of HSPC and therefore a study is needed to assess the safety of this combination, and whether it successfully mobilizes HSPC
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma Cutaneous Lymphoma||Drug: ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination||Phase 1|
HSPC mobilization is normally achieved using cytokines such as G-CSF, or occasionally GM-CSF, often in combination with myelosuppressive chemotherapy.
Studies in the mouse model have shown that retinoids (vitamin A derivatives) can be combined with G-CSF, and that this combination synergizes to enhance HSPC mobilization over that seen with G-CSF alone.
This trial aims to assess the safety and mobilization efficacy of combining mobilizing doses of G-CSF with a standard dose of ATRA, using a treatment regimen derived from the earlier murine studies.
In this phase I pilot study, six patients with multiple myeloma or cutaneous lymphoma will be treated with ATRA plus G-CSF, and safety and toxicity data collected for the two week study drug period plus a further two weeks' follow-up. The primary endpoint is safety and toxicity, the secondary endpoint is an observation of the mobilization efficacy as demonstrated by CD34+ cell counts over the study period. Patients will not undergo stem cell collection during this study, as this is purely an observational study. Participating patients will not be those who would normally be scheduled for stem cell collection and transplantation in the near future, but rather patients with stable disease who are not candidates for imminent transplantation, or who have collected adequate HSPC on previous mobilization attempts and are currently being observed.
Cutaneous lymphoma and multiple myeloma are chosen as suitable disease states for this study as there is in vitro evidence of a possible disease benefit of retinoids in these disorders. If disease response is noted during the study or follow up period, ongoing ATRA will be offered at the discretion of the treating physician.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study of Haematopoietic Stem Cell Mobilization Using G-CSF With ATRA in Patients With Cutaneous Lymphoma and Multiple Myeloma|
|Study Start Date :||March 2005|
|Study Completion Date :||May 2005|
- Toxicity data (NCI-CTC version 2.0 criteria)
- skin toxicity
- mucosal toxicity
- hematologic toxicity
- neurologic toxicity
- treatment response
- CD34+ cell count peak level
- time to CD34+ count peak level
- time to reach level >5 x 10^6.L
- area under curve for duration of time spent with CD34+ count >5 x 10^6/L
- peripheral blood colony forming unit assays
- peak CFU-GEMM level
- time to peak CFU-GEMM level
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00400556
|Peter MacCallum Cancer Center|
|East Melbourne, Victoria, Australia, 3002|
|Principal Investigator:||Kirsten E Herbert, MBBS||Peter MacCallum Cancer Center|
|Principal Investigator:||Miles Prince, MBBS||Peter MacCallum Cancer Center|